AU2002211758A1 - Methods for modulating bladder function - Google Patents
Methods for modulating bladder functionInfo
- Publication number
- AU2002211758A1 AU2002211758A1 AU2002211758A AU1175802A AU2002211758A1 AU 2002211758 A1 AU2002211758 A1 AU 2002211758A1 AU 2002211758 A AU2002211758 A AU 2002211758A AU 1175802 A AU1175802 A AU 1175802A AU 2002211758 A1 AU2002211758 A1 AU 2002211758A1
- Authority
- AU
- Australia
- Prior art keywords
- indol
- dihydro
- chloro
- alkyl
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/341—Urinary incontinence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24107800P | 2000-10-17 | 2000-10-17 | |
US60/241,078 | 2000-10-17 | ||
US28142801P | 2001-04-04 | 2001-04-04 | |
US60/281,428 | 2001-04-04 | ||
PCT/US2001/032204 WO2002032419A2 (en) | 2000-10-17 | 2001-10-16 | Methods for modulating bladder function |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002211758A1 true AU2002211758A1 (en) | 2002-04-29 |
Family
ID=26933980
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002211758A Abandoned AU2002211758A1 (en) | 2000-10-17 | 2001-10-16 | Methods for modulating bladder function |
AU2002213308A Abandoned AU2002213308A1 (en) | 2000-10-17 | 2001-10-17 | Methods of selecting compounds for modulation of bladder function |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002213308A Abandoned AU2002213308A1 (en) | 2000-10-17 | 2001-10-17 | Methods of selecting compounds for modulation of bladder function |
Country Status (23)
Country | Link |
---|---|
US (3) | US6348486B1 (no) |
EP (2) | EP1326597B1 (no) |
JP (2) | JP2004511516A (no) |
KR (1) | KR20030040540A (no) |
CN (1) | CN1287781C (no) |
AR (1) | AR030901A1 (no) |
AT (1) | ATE314061T1 (no) |
AU (2) | AU2002211758A1 (no) |
BR (1) | BR0114718A (no) |
CA (2) | CA2450467C (no) |
CY (1) | CY1105353T1 (no) |
DE (1) | DE60116352T2 (no) |
DK (1) | DK1326597T3 (no) |
ES (1) | ES2253432T3 (no) |
HK (1) | HK1056514A1 (no) |
HU (1) | HUP0303288A2 (no) |
IL (1) | IL155090A0 (no) |
MX (1) | MXPA03003339A (no) |
NO (1) | NO20031580L (no) |
NZ (1) | NZ525301A (no) |
PL (1) | PL360903A1 (no) |
TW (1) | TWI287984B (no) |
WO (2) | WO2002032419A2 (no) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI287984B (en) * | 2000-10-17 | 2007-10-11 | Wyeth Corp | Pharmaceutical composition for modulating bladder function |
WO2002080898A2 (en) * | 2001-04-04 | 2002-10-17 | Wyeth | Methods for treating hyperactive gastric motility |
GB0210397D0 (en) * | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
EP1553932A2 (en) * | 2002-10-21 | 2005-07-20 | Ramot at Tel Aviv University Ltd. | Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
WO2004096767A1 (en) * | 2003-04-25 | 2004-11-11 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
WO2004099442A2 (en) * | 2003-05-06 | 2004-11-18 | University Hospital Of Basel | Kcnma1 as a therapeutic target in cancer treatment |
US20050089559A1 (en) * | 2003-10-23 | 2005-04-28 | Istvan Szelenyi | Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
US20060148782A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both |
PT1530967E (pt) * | 2003-11-13 | 2006-09-29 | Ferring Bv | Embalagem blister e uma forma de dosagem solida que compreende desmopressina. |
EP1688141A1 (en) * | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
WO2007084497A1 (en) * | 2006-01-19 | 2007-07-26 | Wyeth | A novel rat voltage-gated potassium channel |
SE0600482L (sv) * | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
US7960436B2 (en) * | 2006-06-05 | 2011-06-14 | Valeant Pharmaceuticals International | Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators |
US20080045534A1 (en) * | 2006-08-18 | 2008-02-21 | Valeant Pharmaceuticals North America | Derivatives of 1,3-diamino benzene as potassium channel modulators |
US8993593B2 (en) * | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
EP2061465B1 (en) * | 2006-08-23 | 2013-04-10 | Valeant Pharmaceuticals International | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
US8722929B2 (en) * | 2006-10-10 | 2014-05-13 | Valeant Pharmaceuticals International | N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators |
US8030518B2 (en) * | 2006-11-28 | 2011-10-04 | Valeant Pharmaceuticals International | 1,4 diamino bicyclic retigabine analogues as potassium channel modulators |
DE102007012029A1 (de) | 2007-03-13 | 2008-09-18 | Grünenthal GmbH | Verfahren zur Identifizierung der agonistischen Aktivität einer Zielverbindung auf einen Kaliumkanal |
US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
US8563566B2 (en) | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
US8399410B2 (en) | 2007-08-06 | 2013-03-19 | Allergan, Inc. | Methods and devices for desmopressin drug delivery |
US7786146B2 (en) * | 2007-08-13 | 2010-08-31 | Valeant Pharmaceuticals International | Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators |
WO2009037707A2 (en) * | 2007-09-20 | 2009-03-26 | Ramot At Tel Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
DK3085381T3 (en) * | 2008-05-21 | 2018-05-28 | Ferring Bv | ORODISPERSIBLE DESMOPRESSIN TO INCREASE THE INITIAL PERIOD OF SLEEP UNDERSTANDED BY NEW TURRY |
US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
CN102170879B (zh) * | 2008-07-18 | 2014-03-05 | 威朗国际制药公司 | 调控释放制剂及其应用方法 |
WO2011101456A2 (en) * | 2010-02-19 | 2011-08-25 | Medichem S.A. | Stabilized phenylcarbamate derivative in solid state |
WO2013165575A1 (en) * | 2012-04-30 | 2013-11-07 | Scifluor Life Sciences, Llc | Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives |
US10526280B2 (en) | 2014-11-13 | 2020-01-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | (2-amino-4-(arylamino)phenyl carbamates |
US11358930B2 (en) | 2018-04-20 | 2022-06-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Selective potassium channel agonists |
EP3912625A1 (en) | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US37460A (en) * | 1863-01-20 | Improvement in meat-broilers | ||
GB9220570D0 (en) * | 1991-10-21 | 1992-11-11 | Ici Plc | Therapeutic agent |
DE4200259A1 (de) | 1992-01-08 | 1993-07-15 | Asta Medica Ag | Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung |
US5565483A (en) | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
DE19539861A1 (de) | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
US6277978B1 (en) * | 1995-12-22 | 2001-08-21 | University Of Utah Research Foundation | KVLQT1—a long QT syndrome gene |
DE19701694A1 (de) | 1997-01-20 | 1998-07-23 | Asta Medica Ag | Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung |
DE69837267T2 (de) * | 1997-08-12 | 2007-10-31 | Bristol-Myers Squibb Co. | Kcnq kaliumkanäle und verfahren zur deren modulierung |
WO1999021875A1 (en) | 1997-10-24 | 1999-05-06 | University Of Utah Research Foundation | Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies |
WO1999041372A1 (en) * | 1998-02-17 | 1999-08-19 | Astrazeneca Uk Limited | Potassium channel polypeptide |
US6133275A (en) * | 1998-05-06 | 2000-10-17 | Abbott Laboratories | 3-phenylpyrrolidine alpha-1 adrenergic compounds |
US6794161B1 (en) * | 1999-01-26 | 2004-09-21 | Neurosearch A/S | Potassium channels and genes encoding these potassium channels |
ATE342279T1 (de) * | 1999-01-26 | 2006-11-15 | Neurosearch As | Kaliumkanäle und für diese kaliumkanäle kodierende gene |
IT1312224B1 (it) * | 1999-03-23 | 2002-04-09 | Cit Alcatel | Circuito pre/post-distorcitore particolarmente per sistemi aradiofrequenza microonde. |
GB9915414D0 (en) | 1999-07-01 | 1999-09-01 | Glaxo Group Ltd | Medical use |
US6117900A (en) | 1999-09-27 | 2000-09-12 | Asta Medica Aktiengesellschaft | Use of retigabine for the treatment of neuropathic pain |
US6617131B2 (en) * | 2000-03-21 | 2003-09-09 | Aventis Pharma Deutschland Gmbh | Nucleic acid molecule encoding the potassium channel protein, KCNQ5 |
US6767736B2 (en) * | 2000-04-03 | 2004-07-27 | Lexicon Genetics Incorporated | Human ion channel protein and polynucleotides encoding the same |
US6455568B2 (en) * | 2000-07-06 | 2002-09-24 | Wyeth | Combination therapy for inhibiting sphincter incontinence |
US6376486B1 (en) * | 2000-07-06 | 2002-04-23 | American Home Products Corporation | Methods of inhibiting sphincter incontinence |
AU2001286557A1 (en) * | 2000-08-23 | 2002-03-04 | Merck Frosst Canada And Co. | Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists |
TWI287984B (en) | 2000-10-17 | 2007-10-11 | Wyeth Corp | Pharmaceutical composition for modulating bladder function |
US6613786B2 (en) * | 2001-11-02 | 2003-09-02 | Bristol-Myers Squibb Company | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants |
EP1583821A4 (en) * | 2003-01-15 | 2007-07-18 | Millennium Pharm Inc | METHODS AND COMPOSITIONS FOR TREATING UROLOGICAL DISORDERS USING GENES 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579 |
CA2531019A1 (en) * | 2003-06-30 | 2005-01-06 | Takeda Pharmaceutical Company Limited | Preventive/remedy for urinary disturbance |
AU2004272104B2 (en) * | 2003-09-10 | 2011-09-08 | Icagen, Inc | Fused ring heterocycles as potassium channel modulators |
JP2008538784A (ja) * | 2005-04-24 | 2008-11-06 | ワイス | 膀胱機能を調節するための方法 |
WO2007084497A1 (en) * | 2006-01-19 | 2007-07-26 | Wyeth | A novel rat voltage-gated potassium channel |
-
2001
- 2001-10-15 TW TW090125411A patent/TWI287984B/zh not_active IP Right Cessation
- 2001-10-15 US US09/977,828 patent/US6348486B1/en not_active Expired - Fee Related
- 2001-10-16 NZ NZ525301A patent/NZ525301A/en unknown
- 2001-10-16 EP EP01979836A patent/EP1326597B1/en not_active Expired - Lifetime
- 2001-10-16 DK DK01979836T patent/DK1326597T3/da active
- 2001-10-16 HU HU0303288A patent/HUP0303288A2/hu unknown
- 2001-10-16 AT AT01979836T patent/ATE314061T1/de not_active IP Right Cessation
- 2001-10-16 PL PL01360903A patent/PL360903A1/xx not_active Application Discontinuation
- 2001-10-16 MX MXPA03003339A patent/MXPA03003339A/es active IP Right Grant
- 2001-10-16 WO PCT/US2001/032204 patent/WO2002032419A2/en active IP Right Grant
- 2001-10-16 DE DE60116352T patent/DE60116352T2/de not_active Expired - Lifetime
- 2001-10-16 CN CNB018175597A patent/CN1287781C/zh not_active Expired - Fee Related
- 2001-10-16 CA CA2450467A patent/CA2450467C/en not_active Expired - Fee Related
- 2001-10-16 IL IL15509001A patent/IL155090A0/xx unknown
- 2001-10-16 BR BR0114718-8A patent/BR0114718A/pt not_active Application Discontinuation
- 2001-10-16 JP JP2002535657A patent/JP2004511516A/ja not_active Ceased
- 2001-10-16 ES ES01979836T patent/ES2253432T3/es not_active Expired - Lifetime
- 2001-10-16 AR ARP010104848A patent/AR030901A1/es not_active Application Discontinuation
- 2001-10-16 KR KR10-2003-7005291A patent/KR20030040540A/ko not_active Application Discontinuation
- 2001-10-16 AU AU2002211758A patent/AU2002211758A1/en not_active Abandoned
- 2001-10-17 US US10/399,489 patent/US7160684B2/en not_active Expired - Fee Related
- 2001-10-17 CA CA002425742A patent/CA2425742A1/en not_active Abandoned
- 2001-10-17 WO PCT/US2001/032371 patent/WO2002032960A2/en active Application Filing
- 2001-10-17 EP EP01981678A patent/EP1328550A2/en not_active Withdrawn
- 2001-10-17 AU AU2002213308A patent/AU2002213308A1/en not_active Abandoned
- 2001-10-17 JP JP2002536341A patent/JP2004529611A/ja active Pending
-
2003
- 2003-04-08 NO NO20031580A patent/NO20031580L/no not_active Application Discontinuation
- 2003-12-10 HK HK03108976A patent/HK1056514A1/xx not_active IP Right Cessation
-
2006
- 2006-02-08 CY CY20061100173T patent/CY1105353T1/el unknown
- 2006-05-22 US US11/419,714 patent/US20060252104A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1326597B1 (en) | Use of kcnq potassium channel agonists for the manufacture of a medicament for modulating bladder function | |
US7015242B2 (en) | Methods for treating hyperactive gastrointestinal motility | |
US6589986B2 (en) | Methods of treating anxiety disorders | |
US20200392092A1 (en) | Apelin receptor agonists and methods of use thereof | |
US10278960B2 (en) | Sphingosine pathway modulating compounds for the treatment of cancers | |
AU2003211078A1 (en) | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence | |
Sitar | Clinical pharmacokinetics of bambuterol | |
Ozaki et al. | Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro | |
EP2667896A2 (en) | Methods and compositions for treating alzheimer's disease | |
ZA200303798B (en) | Methods for modulating bladder function. | |
EP4282477A2 (en) | Combination comprising sildenafil for use in the treatment of osteoarthritis | |
EA011309B1 (ru) | Составы для ослабления боли, содержащие целекоксиб | |
AU2007201061A1 (en) | Methods for modulating bladder function | |
Ashour et al. | Modulation of plasma uridine concentration by 5-(phenylselenenyl) acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy | |
US11318186B2 (en) | Use of FGF21 in methods of increasing exocrine pancreatic secretion | |
WO2014149973A2 (en) | Compositions and methods for treating bone diseases | |
WO2011138977A1 (en) | Method of preventing or treating body weight-related disorders by employing vaspin | |
CN101014369A (zh) | 利用cox—2选择性抑制剂和ltb4受体拮抗剂的组合用于治疗炎症和疼痛的组合物 | |
WO2021044430A1 (en) | Anti-fibrotic compounds and use thereof | |
WO2021055564A1 (en) | Methods of treating phosphate concentration disorders with l-baiba | |
US20190111061A1 (en) | Compositions and methods targeting hcn channels for breathing therapeutics | |
ULC | Pr MYLAN-TAMSULOSIN | |
CA2413906A1 (en) | Carboxyalkylether-acat inhibitor combinations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |